SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as its community rallies around the idea of OG meme season and community strength, emphasizing the value of shared culture over traditional financial metrics. Fueling the excitement is a collective push for increased visibility and a potential moonshot, with members actively coordinating efforts to trend and engage online. The broader narrative centers on reviving the spirit of early meme-based crypto projects.

Aventus Network

Aventus Network ($AVT) is trending, with community members citing its real-world technology and partnerships as potential catalysts. Discussions also highlight Aventus's integration with Polkadot and its possible listing on major exchanges like Binance. Some traders are comparing $AVT to $CTX, anticipating similar gains.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors debate its recent pullback and potential bottom, with some citing the overall downturn in AI stocks as a factor. Despite the volatility, the community expresses long-term confidence in the company's fundamentals, particularly its Microsoft deal and growth potential in the data center and AI infrastructure space. Bullish investors anticipate a rebound around earnings, while others are concerned about the lack of an official earnings date.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards following its Q3 earnings release, with analysts pointing to a Brazilian tax dispute as a key factor impacting profitability. The community is actively debating whether this is a temporary setback or a sign of deeper issues, and if the company is overvalued. Some traders are anticipating further downgrades and a potential drop, while others see a buying opportunity amidst the uncertainty.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to recent news of a direct offering and its potential impact on the company's AI chip development, with discussions centering on whether the capital raise will fuel growth or dilute shareholder value. Some traders are pointing to the institutional investment as a positive signal, while others are concerned about the offering's timing after positive news. The community is also debating the validity and potential of the company's APU technology in comparison to industry giants.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending after securing significant funding to advance its schizophrenia treatment through Phase 3 trials, sparking excitement about its potential. The community is actively discussing the implications of this funding for the company's future and the potential for a significant price increase. Some traders are wary, however, and point to prior dilution.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to a sharp decline following its Q3 earnings report, despite exceeding revenue expectations. Community discussions revolve around the company's cautious outlook and concerns about the automotive market, with some viewing the sell-off as an overreaction and a buying opportunity, while others point to valuation concerns and potential tariff impacts. The broader context involves renewed scrutiny on U.S.-China trade relations and their potential effect on the semiconductor industry.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as investors discuss its high short interest and potential for a squeeze, alongside commentary around a recent CFO hire.  The stock is also garnering attention as a possible acquisition target, with some viewing the current price as oversold, while others cite expensive salads and profitability concerns.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following strong Q2 earnings, with significant procedure growth and increased da Vinci 5 placements driving positive sentiment. However, concerns persist within the community regarding margin pressures from tariffs and rising costs, leading to debates about the stock's valuation and future performance. Some traders are eyeing specific price levels for potential entries or exits, while others debate the long-term impact of competition and evolving healthcare trends.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending as investors react to a reported earnings beat and discuss the company's potential in AI data centers. Community members are highlighting the company's growth, with some expressing optimism about future price targets. Discussions also include the impact of Bitcoin's price movements and analyst ratings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Activist investor Jana Partners has quietly built a stake in Cooper Cos. and reportedly plans to push the California-based medical device maker to explore strategic alternatives, including a potential merger between its contact-lens business and rival Bausch + Lomb.The size of Jana’s stake has not been disclosed, but the investor is apparently preparing to engage with Cooper’s management to influence direction, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/activist-jana-takes-stake-in-cooper-a-maker-of-medical-devices-20ffbe9c?mod=hp_lead_pos6">reported</a>,&nbsp;citing people familiar with the matter.Bausch + Lomb CEO Brent Saunders, known for his aggressive dealmaking, said he would be open to such a combination, and that it could “strengthen competition and create a more scaled company in the contact-lens segment.”Pressure To Improve Returns&nbsp;Beyond pushing for a merger, Jana Partners also&nbsp;reportedly wants Cooper to take a hard look at how it’s running the business. The activist investor plans to press the company to use its capital more efficiently and deliver stronger returns for shareholders, according to people familiar with the matter.Jana believes Cooper’s two main units, including CooperVision, which makes contact lenses, and CooperSurgical, focused on women’s health and fertility, don’t really fit together and have little overlap and simplifying the structure could improve the company’s performance.Cooper’s DeclineCooper, valued at about $14 billion, reported $3.9 billion in revenue for 2024, with the CooperVision segment contributing over two-thirds of total sales.The firm reportedly maintains that it remains confident in its dual-market strategy, arguing that both segments operate in growing global markets and complement each other strategically.However, Cooper’s contact-lens business has lagged rivals,&nbsp;according to the report, while its women’s health segment has faced margin pressure after a series of acquisitions that have yet to deliver returns.Why Bausch + Lomb Fits Into the PictureJana believes there are potential buyers for both Cooper divisions, but sees a tie-up between CooperVision and Bausch + Lomb as particularly appealing to investors.Bausch + Lomb, with a market capitalization of about $5.3 billion, was itself spun out from a larger healthcare company under Saunders’s leadership. Both firms compete with Johnson &amp; Johnson and Alcon in the global contact-lens market, and a merger could create a stronger challenger in the space.Jana’s Track Record in ActivismJana has a history of driving corporate shake-ups. It previously pushed for strategic reviews at Frontier Communications, which was later acquired by Verizon, and Markel, which is still under review.Earlier this year, Jana struck an agreement with Lamb Weston, the frozen potato giant, leading to the addition of six new board members after the activist pressed for changes.How Is Stocktwits Reading The Mood?On Stocktwits, retail sentiment was ‘bullish’ for Cooper and ‘bearish’ for Bausch + Lomb, with overall message volume remaining ‘low’ for both.While&nbsp;<a href="https://stocktwits.com/symbol/COO">Cooper Cos.’ stock</a> has declined 22% so far this year,&nbsp;<a href="https://stocktwits.com/symbol/BLCO">Bausch + Lomb’s stock</a> has fallen 17% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Activist Investor Turns Up Heat On Cooper, Urges Bausch + Lomb Merger To Boost Returns: Report

Jana Partners is urging Cooper to improve capital use and returns, saying its contact-lens and women’s health units lack strategic fit and drag on performance.

Equity

BLCO vs. DHR: Which Stock Should Value Investors Buy Now?

BLCO vs. DHR: Which Stock Is the Better Value Option?

Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +16.67% and +2.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 30th

ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.

New Strong Sell Stocks for July 24th

COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty

Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to weigh on sales growth, earnings, and investor sentiment. Brokerage cut its price target to $15 from $24, based on 9.5x its 2026 EBITDA estimate of $1.0 billion.

Bausch Health Companies Inc. shares (BHC) jumped over 7% in after-hours trading on Wednesday following a solid fourth-quarter earnings report that beat revenue estimates and reaffirmed strong guidance for 2025.The company posted Q4 revenue of $2.56 billion, surpassing the consensus estimate of $2.51 billion, while adjusted earnings per share (EPS) of $1.14 narrowly topped expectations of $1.13.&nbsp;Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $935 million, up from $869 million a year ago.CEO Thomas Appio highlighted 2024 as a year of "delivering on our commitments," with results landing at the high end of revenue guidance and exceeding expectations for adjusted EBITDA (excluding Bausch + Lomb) and operating cash flow.Salix, the company's gastrointestinal and hepatology division, generated $634 million in Q4 revenue, up 9% year-over-year. This was largely driven by Xifaxan, a treatment for irritable bowel syndrome and traveler's diarrhea, which posted 16% growth.&nbsp;The Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.For 2025, Bausch Health projects revenue between $9.90 billion and $10.15 billion, above the consensus estimate of $9.89 billion.&nbsp;The company also forecasts FY25 adjusted EBITDA between $3.525 billion and $3.675 billion.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BHC_sentiment_and_message_volume_Feb_19_07562dbe77.png" alt="BHC sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>BHC sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned 'extremely bullish' following the earnings report, with message volume spiking 1,900% on Wednesday.One user highlighted "very good organic revenue growth and solid guidance," expecting a strong bounce for the stock.&nbsp;Another hoped for a rally past $20 per share.<stembedurl>https://stocktwits.com/Neildc/message/604885428</stembedurl><stembedurl>https://stocktwits.com/Maxgluteal/message/604910108</stembedurl>However, BHC shares remain about 35% below analysts' average target price of $8.83.&nbsp;The stock has lost over 19% year-to-date.&nbsp;&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Bausch & Lomb to shake up contact lenses with deal off the table

Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Bausch + Lomb Corp

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

BLCO
Bausch + Lomb Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLCO News

BLCOBausch + Lomb Corp.